Leonardo Guizzetti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Leonardo Guizzetti has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Vipul Jairath
Division of Gastroenterology, Western University, London, Ontario, Canada
15 shared publications - Christopher Ma
Division of Gastroenterology & Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary , Calgary, Alberta
9 shared publications - Brian Gordon Feagan
Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada
7 shared publications Reena Khanna
Robarts Clinical Trials Inc, London, Canada; Department of Medicine, University of Western Ontario, London, Canada
4 shared publicationsVipul Jairath
4 shared publicationsBrian G. Feagan
Robarts Clinical Trials Inc, London, Canada; Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada; Department of Medicine, University of Western Ontario, London, Canada
3 shared publications
Latest Publications
- 30 June 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 106 (4) , 1272-1287
Harnessing greater statistical power: Comprehensive evaluation of disease modifying treatment effects across all or multiple post-baseline visits compared to the last visit for Alzheimer's disease clinical trials
Background: In Alzheimer's disease (AD) clinical trials, efficacy inference is traditionally based on the last visit (e.g., 18 months). However, recent studies suggest that disease-modifying treatment effects may emerge as early as 3 months post-baseline. Objective: To explore this further, our study aimed to assess the increased statistical power achieved by incorporating all or multiple post-baseline visits to estimate treatment effect, compared to relying solely on the last visit. Methods: We developed explicit formulas for the basis functions of the natural cubic spline model, ensuring compatibility with standard SAS procedures. Through simulations using disease progression trajectories from Clarity-AD and TRAILBLAZER-ALZ 2 trials, we comprehensively evaluated various models in terms of power and type I error. Additionally, we offer SAS codes that to facilitate seamless implementation of different modeling approaches. Results: Simulations based on ClarityAD and TRAILBLAZER-ALZ 2 disease trajectories demonstrated that models incorporating multiple or all post-baseline visits yield greater power than those using only the last visit, while maintaining Type I error control. Furthermore, when three post-baseline visits were included, adding more visits resulted in minimal power gains. Conclusions: Our findings support prioritizing statistical models that incorporate multiple or all post-baseline visits for treatment efficacy inference, as they offer greater efficiency than models relying solely on the last visit.
- 30 June 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 106 (4) , 1272-1287
Harnessing greater statistical power: Comprehensive evaluation of disease modifying treatment effects across all or multiple post-baseline visits compared to the last visit for Alzheimer's disease clinical trials
Background: In Alzheimer's disease (AD) clinical trials, efficacy inference is traditionally based on the last visit (e.g., 18 months). However, recent studies suggest that disease-modifying treatment effects may emerge as early as 3 months post-baseline. Objective: To explore this further, our study aimed to assess the increased statistical power achieved by incorporating all or multiple post-baseline visits to estimate treatment effect, compared to relying solely on the last visit. Methods: We developed explicit formulas for the basis functions of the natural cubic spline model, ensuring compatibility with standard SAS procedures. Through simulations using disease progression trajectories from Clarity-AD and TRAILBLAZER-ALZ 2 trials, we comprehensively evaluated various models in terms of power and type I error. Additionally, we offer SAS codes that to facilitate seamless implementation of different modeling approaches. Results: Simulations based on ClarityAD and TRAILBLAZER-ALZ 2 disease trajectories demonstrated that models incorporating multiple or all post-baseline visits yield greater power than those using only the last visit, while maintaining Type I error control. Furthermore, when three post-baseline visits were included, adding more visits resulted in minimal power gains. Conclusions: Our findings support prioritizing statistical models that incorporate multiple or all post-baseline visits for treatment efficacy inference, as they offer greater efficiency than models relying solely on the last visit.
- Open Access
- 18 February 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (8) , 1391-1395
Comparison Between Dynamic Models for Predicting Response to Corticosteroids in Alcohol‐Associated Hepatitis: A Global Cohort Study
Several dynamic models predict mortality and corticosteroid response in alcohol‐associated hepatitis (AH), yet no consensus exists on the most effective model. This study aimed to assess predictive models for corticosteroid response and short‐term mortality in severe AH within a global cohort. We conducted a multi‐national study of patients with severe AH treated with corticosteroids for at least 7 days, enrolled between 2009 and 2019. Dynamic models—Lille‐4, Lille‐7, trajectory of serum bilirubin (TSB), and neutrophil‐to‐lymphocyte ratio (NLR)—were used to estimate 30‐ and 90‐day mortality. Lille‐7 demonstrated the highest accuracy for both 30‐ and 90‐day mortality.
- 18 February 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (8) , 1391-1395
Open AccessComparison Between Dynamic Models for Predicting Response to Corticosteroids in Alcohol‐Associated Hepatitis: A Global Cohort Study
Several dynamic models predict mortality and corticosteroid response in alcohol‐associated hepatitis (AH), yet no consensus exists on the most effective model. This study aimed to assess predictive models for corticosteroid response and short‐term mortality in severe AH within a global cohort. We conducted a multi‐national study of patients with severe AH treated with corticosteroids for at least 7 days, enrolled between 2009 and 2019. Dynamic models—Lille‐4, Lille‐7, trajectory of serum bilirubin (TSB), and neutrophil‐to‐lymphocyte ratio (NLR)—were used to estimate 30‐ and 90‐day mortality. Lille‐7 demonstrated the highest accuracy for both 30‐ and 90‐day mortality.
- 14 November 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (7) , 1576-1584
Effectiveness of Ustekinumab for Patients With Moderate-to-Severe Ulcerative Colitis: A Multicenter Real-World Canadian Study
INTRODUCTION: We aimed to evaluate the real-world effectiveness and safety of ustekinumab for the treatment of both bio-naive and bio-exposed ulcerative colitis patients in a real-world setting. METHODS: Retrospective, Canadian multicenter cohort study. Primary outcomes were clinical remission and endoscopic remission. Key secondary outcomes included composite clinical and endoscopic response, safety, and persistence. Univariable logistic regression was conducted to examine associations between baseline factors and 12-month clinical and endoscopic response and remission. The primary focus was on the association between these outcomes and bioexposure status. RESULTS: A total of 198 patients were included, of whom 47.5% were female and 85.9% were younger than 65 years. The majority had severe endoscopic activity at baseline (47.5%, n = 87) and were bio-exposed (88.8%, n = 176; 33%, n = 66 previous failure of 3 or more biologics). Patients were followed for a median of 12.8 (interquartile range 8.2–22.1) months after induction. The overall clinical remission rates were 41.3% (69/167), 38.1% (56/147), and 43.6% (58/133) at 3, 6 and 12 months, respectively. Endoscopic remission rates (Mayo endoscopy score = 0) were 8.0% (7/88), 18.7% (23/123), and 12.5% (11/88) at 3, 6, and 12 months, respectively, and consistently higher in bio-naive patients compared with bio-exposed patients through 12 months (P < 0.05 at all time points). Bio-naive patients were more likely to achieve endoscopic remission compared with bio-exposed (hazard ratio = 5.40, 95% confidence interval [CI]: 1.08–26.93). Adverse events were reported in 14.1% (18/198). DISCUSSION: In a highly refractory and largely bio-exposed population, a substantial proportion of patients with ulcerative colitis treated with ustekinumab can achieve clinical and endoscopic outcomes of importance after 12 months. Previous biologic exposure is associated with lower rates of endoscopic remission.
- 14 November 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (7) , 1576-1584
Effectiveness of Ustekinumab for Patients With Moderate-to-Severe Ulcerative Colitis: A Multicenter Real-World Canadian Study
INTRODUCTION: We aimed to evaluate the real-world effectiveness and safety of ustekinumab for the treatment of both bio-naive and bio-exposed ulcerative colitis patients in a real-world setting. METHODS: Retrospective, Canadian multicenter cohort study. Primary outcomes were clinical remission and endoscopic remission. Key secondary outcomes included composite clinical and endoscopic response, safety, and persistence. Univariable logistic regression was conducted to examine associations between baseline factors and 12-month clinical and endoscopic response and remission. The primary focus was on the association between these outcomes and bioexposure status. RESULTS: A total of 198 patients were included, of whom 47.5% were female and 85.9% were younger than 65 years. The majority had severe endoscopic activity at baseline (47.5%, n = 87) and were bio-exposed (88.8%, n = 176; 33%, n = 66 previous failure of 3 or more biologics). Patients were followed for a median of 12.8 (interquartile range 8.2–22.1) months after induction. The overall clinical remission rates were 41.3% (69/167), 38.1% (56/147), and 43.6% (58/133) at 3, 6 and 12 months, respectively. Endoscopic remission rates (Mayo endoscopy score = 0) were 8.0% (7/88), 18.7% (23/123), and 12.5% (11/88) at 3, 6, and 12 months, respectively, and consistently higher in bio-naive patients compared with bio-exposed patients through 12 months (P < 0.05 at all time points). Bio-naive patients were more likely to achieve endoscopic remission compared with bio-exposed (hazard ratio = 5.40, 95% confidence interval [CI]: 1.08–26.93). Adverse events were reported in 14.1% (18/198). DISCUSSION: In a highly refractory and largely bio-exposed population, a substantial proportion of patients with ulcerative colitis treated with ustekinumab can achieve clinical and endoscopic outcomes of importance after 12 months. Previous biologic exposure is associated with lower rates of endoscopic remission.
- Open Access
- 24 October 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (11)
Comparative effectiveness of different corticosteroid regimens in severe alcohol-associated hepatitis
Export
- 24 October 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (11)
Open AccessComparative effectiveness of different corticosteroid regimens in severe alcohol-associated hepatitis
Export
- 1 August 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (2) , e233038
Reliability of CT Enterography for Describing Fibrostenosing Crohn Disease
Maximal associated small bowel dilation, stricture length, and maximal stricture wall thickness at CT enterography can reliably describe Crohn disease stricture severity and serve as eligibility or efficacy criteria in antistricture therapy trials.
- 1 August 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (2) , e233038
Reliability of CT Enterography for Describing Fibrostenosing Crohn Disease
Maximal associated small bowel dilation, stricture length, and maximal stricture wall thickness at CT enterography can reliably describe Crohn disease stricture severity and serve as eligibility or efficacy criteria in antistricture therapy trials.
- Open Access
- 16 July 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (21) , 4148-4162
Extending the DeLong algorithm for comparing areas under correlated receiver operating characteristic curves with missing data
A nonparametric method proposed by DeLong et al in 1988 for comparing areas under correlated receiver operating characteristic curves is used widely in practice. However, the DeLong method as implemented in popular software quietly deletes individuals with any missing values, yielding potentially invalid and/or inefficient results. We simplify the DeLong algorithm using ranks and extend it to accommodate missing data by using a mixed model approach for multivariate data. Simulation results demonstrate the validity and efficiency of our procedure for data missing at random. We illustrate our proposed procedure in SAS, Stata, and R using the original DeLong data.
- 16 July 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (21) , 4148-4162
Open AccessExtending the DeLong algorithm for comparing areas under correlated receiver operating characteristic curves with missing data
A nonparametric method proposed by DeLong et al in 1988 for comparing areas under correlated receiver operating characteristic curves is used widely in practice. However, the DeLong method as implemented in popular software quietly deletes individuals with any missing values, yielding potentially invalid and/or inefficient results. We simplify the DeLong algorithm using ranks and extend it to accommodate missing data by using a mixed model approach for multivariate data. Simulation results demonstrate the validity and efficiency of our procedure for data missing at random. We illustrate our proposed procedure in SAS, Stata, and R using the original DeLong data.
- 5 February 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (4) , e30869
Temporal trends of splenectomy in pediatric hospitalizations with hereditary spherocytosis from 2000 to 2019: A national survey
Background: Total and partial splenectomy are used in pediatric patients with hereditary spherocytosis to resolve anemia and hemolytic complications. Procedure: Data from the Healthcare Cost and Utilization Project's Kid's Inpatient Database was used to profile and describe temporal trends in pediatric (≤18 years) hospital admissions in the United States from 2000 to 2019 data release years. Survey sampling methods were used to produce national estimates. Results: From 2000 to 2019, the use of splenectomy declined overall, from 427 to 206 weighted procedures (difference = 222, 95% confidence interval [CI]: 124–320; p < .0001); the risk of undergoing splenectomy during admission also declined from 56.7% to 38.7% (risk difference = 17.9 percentage points [p.p.], 95% CI: 9.7–26.1; p < .0001). Total splenectomy was mostly used. Age at time of splenectomy increased 10.2 years (difference = 1.6 years, 95% CI: 0.6–2.7; p = .0018). The risk of splenectomy increased with age until 10 years, then leveled off until 18 years. The proportion of children aged ≤5 years undergoing splenectomy decreased from 27.7% to 11.2% in 2019 (risk difference: 16.5 p.p., 95% CI: 7.3–25.7; p = .0004). The strongest clinical predictors of splenectomy, adjusting for patient‐ and hospital‐level characteristics, were a co‐diagnosis of symptomatic cholelithiasis (adjusted odds ratio [aOR] = 3.18, 95% CI: 1.92–5.28; p < .0001) and splenomegaly or hypersplenism (aOR = 2.52, 95% CI: 1.74–3.65; p < .0001). Risk of splenectomy with splenomegaly or hypersplenism increased over time. Conclusion: Splenectomy was delayed until age greater than 10 years. Older age, co‐diagnosis with splenomegaly or hypersplenism, or symptomatic cholelithiasis were strongest clinical predictors of splenectomy. Conservative management of hereditary spherocytosis appears to be more common.
- 5 February 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (4) , e30869
Temporal trends of splenectomy in pediatric hospitalizations with hereditary spherocytosis from 2000 to 2019: A national survey
Background: Total and partial splenectomy are used in pediatric patients with hereditary spherocytosis to resolve anemia and hemolytic complications. Procedure: Data from the Healthcare Cost and Utilization Project's Kid's Inpatient Database was used to profile and describe temporal trends in pediatric (≤18 years) hospital admissions in the United States from 2000 to 2019 data release years. Survey sampling methods were used to produce national estimates. Results: From 2000 to 2019, the use of splenectomy declined overall, from 427 to 206 weighted procedures (difference = 222, 95% confidence interval [CI]: 124–320; p < .0001); the risk of undergoing splenectomy during admission also declined from 56.7% to 38.7% (risk difference = 17.9 percentage points [p.p.], 95% CI: 9.7–26.1; p < .0001). Total splenectomy was mostly used. Age at time of splenectomy increased 10.2 years (difference = 1.6 years, 95% CI: 0.6–2.7; p = .0018). The risk of splenectomy increased with age until 10 years, then leveled off until 18 years. The proportion of children aged ≤5 years undergoing splenectomy decreased from 27.7% to 11.2% in 2019 (risk difference: 16.5 p.p., 95% CI: 7.3–25.7; p = .0004). The strongest clinical predictors of splenectomy, adjusting for patient‐ and hospital‐level characteristics, were a co‐diagnosis of symptomatic cholelithiasis (adjusted odds ratio [aOR] = 3.18, 95% CI: 1.92–5.28; p < .0001) and splenomegaly or hypersplenism (aOR = 2.52, 95% CI: 1.74–3.65; p < .0001). Risk of splenectomy with splenomegaly or hypersplenism increased over time. Conclusion: Splenectomy was delayed until age greater than 10 years. Older age, co‐diagnosis with splenomegaly or hypersplenism, or symptomatic cholelithiasis were strongest clinical predictors of splenectomy. Conservative management of hereditary spherocytosis appears to be more common.
- Open Access
- 8 February 2022
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 20 (11) , 2598-2606
Responsiveness of Magnetic Resonance Enterography Indices for Evaluation of Luminal Disease Activity in Crohn’s Disease
- 8 February 2022
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 20 (11) , 2598-2606
Open AccessResponsiveness of Magnetic Resonance Enterography Indices for Evaluation of Luminal Disease Activity in Crohn’s Disease
- 1 July 2021
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 19 (7) , 1497-1498.e1
Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn’s Disease Patients Already on Every-4-Week Dosing
- 1 July 2021
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 19 (7) , 1497-1498.e1
Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn’s Disease Patients Already on Every-4-Week Dosing
- Open Access
- 1 March 2021
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 4 (Supplement) , 92-93
A113 ANNUAL COLONOSCOPY VOLUME IS NOT PREDICTIVE OF COLONOSCOPY QUALITY - FINDINGS FROM THE SOUTHWEST ONTARIO COLONOSCOPY COHORT
Performing a minimum number of colonoscopies annually has been proposed by some jurisdictions as a requirement for maintaining privileges. However, this practice is supported by limited evidence. The objective of this study was to determine if annual colonoscopy volume was associated with colonoscopy quality metrics. A population-based study was performed using the Southwest Ontario Colonoscopy cohort, which consists of all adult patients who underwent colonoscopy between April 2017 and Oct 2018 at 21 academic and community hospitals within the health region. Data were collected through a mandatory quality assurance form completed after each procedure and pathology reports were manually reviewed. Physician annualized colonoscopy volumes were compared by correlation analysis to each quality-related outcome, by means of the area under the receiver operating characteristics curve (AUROC), and logistic regression. The prognostic value of colonoscopy volume was also adjusted for case-mix and potential confounders in separate regression analyses for each outcome. The primary outcome was ADR. Secondary outcomes were polyp detection rate (PDR), sessile serrated polyp detection rate (SSPDR), and cecal intubation. A total of 47,195 colonoscopies were performed by 75 physicians (37.5% by gastroenterologists, 60% by general surgeons, 2.5% others). There were no clear relationships between annual colonoscopy volumes and study outcomes. Colonoscopy volume was not associated with ADR (OR 1.03, 95% CI 0.96–1.10, p=0.48) and corresponded to an AUROC not significantly different from the null (AUROC 0.52, 95% CI 0.43–0.61, p=0.65). Multi-variable regression adjusting for case-mix also demonstrated no predictive value of annual colonoscopy volume for the primary outcome (OR 1.03, 95% CI 0.94–1.12, p=0.55). Similarly, analyses of secondary outcomes failed to find an association between colonoscopy volume and PDR, SSPDR, or cecal intubation (Table 1). Annual colonoscopy volumes do not predict ADR, PDR, SSPDR, or cecal intubation rate. Results of unconditional and conditional approaches for examining the predictive value of annual colonoscopy volume for quality related outcomes. None
- 1 March 2021
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 4 (Supplement) , 92-93
Open AccessA113 ANNUAL COLONOSCOPY VOLUME IS NOT PREDICTIVE OF COLONOSCOPY QUALITY - FINDINGS FROM THE SOUTHWEST ONTARIO COLONOSCOPY COHORT
Performing a minimum number of colonoscopies annually has been proposed by some jurisdictions as a requirement for maintaining privileges. However, this practice is supported by limited evidence. The objective of this study was to determine if annual colonoscopy volume was associated with colonoscopy quality metrics. A population-based study was performed using the Southwest Ontario Colonoscopy cohort, which consists of all adult patients who underwent colonoscopy between April 2017 and Oct 2018 at 21 academic and community hospitals within the health region. Data were collected through a mandatory quality assurance form completed after each procedure and pathology reports were manually reviewed. Physician annualized colonoscopy volumes were compared by correlation analysis to each quality-related outcome, by means of the area under the receiver operating characteristics curve (AUROC), and logistic regression. The prognostic value of colonoscopy volume was also adjusted for case-mix and potential confounders in separate regression analyses for each outcome. The primary outcome was ADR. Secondary outcomes were polyp detection rate (PDR), sessile serrated polyp detection rate (SSPDR), and cecal intubation. A total of 47,195 colonoscopies were performed by 75 physicians (37.5% by gastroenterologists, 60% by general surgeons, 2.5% others). There were no clear relationships between annual colonoscopy volumes and study outcomes. Colonoscopy volume was not associated with ADR (OR 1.03, 95% CI 0.96–1.10, p=0.48) and corresponded to an AUROC not significantly different from the null (AUROC 0.52, 95% CI 0.43–0.61, p=0.65). Multi-variable regression adjusting for case-mix also demonstrated no predictive value of annual colonoscopy volume for the primary outcome (OR 1.03, 95% CI 0.94–1.12, p=0.55). Similarly, analyses of secondary outcomes failed to find an association between colonoscopy volume and PDR, SSPDR, or cecal intubation (Table 1). Annual colonoscopy volumes do not predict ADR, PDR, SSPDR, or cecal intubation rate. Results of unconditional and conditional approaches for examining the predictive value of annual colonoscopy volume for quality related outcomes. None